Selegiline Transdermal System: In the Treatment of Major Depressive DisorderA Viewpoint by J. Alexander Bodkin

被引：0
|
作者：
J. Alexander Bodkin
机构：
[1] Harvard Medical School,Consolidated Department of Psychiatry
来源：
Drugs | 2007年 / 67卷 / 2期
关键词：
D O I：
10.2165/00003495-200767020-00007
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：266 / 266
相关论文
共 50 条
  • [31] Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials
    Pae, Chi-Un
    Patkar, Ashwin A.
    Jang, Saeheon
    Portland, Kimberly B.
    Jung, Sungwon
    Nelson, J. Craig
    CNS SPECTRUMS, 2014, 19 (04) : 324 - 329
  • [32] Symptoms of sexual dysfunction in patients treated for major depressive disorder: A meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale
    Clayton, Anita H.
    Campbell, Bryan J.
    Favit, Antonella
    Yang, Ying
    Moonsammy, George
    Piontek, Catherine M.
    Amsterdam, Jay D.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (12) : 1860 - 1866
  • [33] Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
    Citrome, Leslie
    Goldberg, Joseph F.
    Portland, Kimberly Blanchard
    JOURNAL OF AFFECTIVE DISORDERS, 2013, 151 (02) : 409 - 417
  • [34] Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
    Kitaichi, Yuji
    Inoue, Takeshi
    Mitsui, Nobuyuki
    Nakagawa, Shin
    Kameyama, Rie
    Hayashishita, Yoshiyuki
    Shiga, Tohru
    Kusumi, Ichiro
    Koyama, Tsukasa
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 1591 - 1594
  • [35] Selegiline transdermal system in the prevention of relapse of major depressive disorder - A 52-week, double-blind, placebo-substitution, parallel-group clinical trial
    Amsterdam, Jay D.
    Bodkin, J. Alexander
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (06) : 579 - 586
  • [36] Modulating the serotonin system in the treatment of major depressive disorder
    Morrissette, Debbi Ann
    Stahl, Stephen M.
    CNS SPECTRUMS, 2014, 19 : 57 - 68
  • [37] Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects
    Azzaro, Albert J.
    VanDenBerg, Chad M.
    Blob, Lawrence F.
    Kemper, Eva M.
    Sharoky, Melvin
    Oren, Dan A.
    Campbell, Bryan J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (08): : 933 - 944
  • [38] Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence
    Elkashef, Ahmed
    Fudala, Paul J.
    Gorgon, Liza
    Li, Shou-Hua
    Kahn, Roberta
    Chiang, Nora
    Vocci, Frank
    Collins, Joseph
    Jones, Karen
    Boardman, Kathy
    Sather, Mike
    DRUG AND ALCOHOL DEPENDENCE, 2006, 85 (03) : 191 - 197
  • [39] Treatment effects of selegiline transdermal system on symptoms of MDD: A meta-analysis of placebo-controlled efficacy trials
    Robinson, Donald
    Gilmor, Michelle L.
    Yang, Ying
    MoonsamMy, George I.
    Azzaro, Albert J.
    Oren, Dan A.
    Campbell, Bryan
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 232S - 232S
  • [40] In appreciation of Alexander J. Pugh, on the occasion of his retirement from formal roles in the System Dynamics Society
    Morecroft, J
    Richardson, G
    Barlas, Y
    SYSTEM DYNAMICS REVIEW, 1998, 14 (01) : 100 - 101
12345